Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / Canada

Valeant's Strategic Purchase Viewed Favourably

May 2011 | Industry Trend Analysis

BMI View: We view Valeant's move to purchase Lithuanian company Sanitas favourably, particularly in the wake of its failed hostile bid for Cephalon earlier in 2011.The premium Valeant is prepared to pay returns Sanitas's valuation to pre-economic crisis levels of 2008, but its future earnings potential has been buoyed substantially by the potential for synergies between the firms. It is clear that Valeant will use the purchase as a launch pad for aggressive expansion into Russia.

To read the full article, please choose one of the following options:

Subcribers please log in

Emerging Europe InsightEmerging Europe Channels Emerging Europe Countries